Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-κB translocation

Yuan, Zhiyi; Liao, Yu Kuang; Tian, Gang; Li, Hua; Jia, Yong; Zhang, Haigang; Tan, Zhenghuai; Li, Xiaohui; Deng, Wen; Liu, Kangdong; Zhang, Yiguan

doi:10.1016/j.jep.2011.08.066

Cited by 49 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been used for thousands of years in China for hemostasis [9]. Nowadays, a growing number of literatures have focused on the extensively pharmacological activities of Radix notoginseng on the cardiovascular system [10][11][12]. Panax notoginseng saponins (PNS) are the main active ingredients of Radix notoginseng.…”

Section: Introductionmentioning

confidence: 99%

Notoginsenoside R1 Protects HUVEC Against Oxidized Low Density Lipoprotein (Ox-LDL)-Induced Atherogenic Response via Down-Regulating miR-132

Fu¹,

Yin²,

Nie³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Radix notoginseng is a well-known traditional Chinese herbal medicine, has extensively pharmacological activities in cardiovascular system. Notoginsenoside R1 (NGR1) is one main active ingredient of Radix notoginseng. The purpose of this study was to evaluate the functional effects of NGR1 on atherosclerosis (AS). Methods: Human umbilical vascular endothelial cells (HUVECs) were subjected to oxidized low density lipoprotein (ox-LDL), before which cells were preconditioned with NGR1. Cell Counting Kit-8 (CCK-8) assay, flow cytometry, Transwell assay, quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were carried out to assess the impacts of ox-LDL and NGR1 on HUVECs. Besides, the expression of microRNA-132 (miR-132), and the regulatory role of miR-132 in Matrix Gla Protein (MGP) expression were measured by qRT-PCR and Western blot. Results: NGR1 pre-conditioning prevented ox-LDL-induced apoptosis, migration and overproduction of Monocyte Chemoattractant Protein 1 (MCP-1) and Intercellular Adhesion Molecule 1 (ICAM-1). miR-132 was up-regulated in response to ox-LDL while was down-regulated by NGR1 pre-conditioning. The protective actions of NGR1 in ox-LDL-treated HUVECs were enhanced by miR-132 inhibitor, while were attenuated by miR-132 mimic. Besides, the up-regulated miR-132 could further decrease the expression of MGP, which acted as an anti-migratory and anti-adhesive factor. Furthermore, ox-LDL-induced the activation of c-Jun N-terminal Kinase (JNK) and Nuclear Factor Kappa B (NF-κB) pathways were partially attenuated by NGR1, and were fully eliminated by NGR1 treatment together with MGP overexpression. Conclusion: NGR1 prevents ox-LDL-induced apoptosis, migration and adhesion-related molecule release in HUVECs possibly via down-regulating miR-132, and subsequent up-regulating MGP.

show abstract

Section: Introductionmentioning

confidence: 99%

Notoginsenoside R1 Protects HUVEC Against Oxidized Low Density Lipoprotein (Ox-LDL)-Induced Atherogenic Response via Down-Regulating miR-132

Fu¹,

Yin²,

Nie³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Panax notoginseng has beneficial effects on atherosclerotic diseases such as cardiovascular disease (Yang et al , ), cerebral ischemic disease (Shi et al , ) and other diseases including diabetes (Uzayisenga et al , ; Kitamura et al , ), tumor (Yang et al , ; Li et al , ; Lee et al , ), hepatic injury (Wang et al , ; Zhang et al , ) and bone fracture (Wang et al, ). For in the cardiovascular system, it attenuates atherosclerosis, through inhibiting the formation of foam cells and lowering cholesterol ester level (Jia et al , ), demonstrating antiinflammatory and anti‐adhesion effects (Yuan et al , ) and reducing the size of atherosclerotic plaques (Liu et al , ). The comparison of three common panax species— P. notoginseng , Panax ginseng C. A. Meyer (Chinese and Korean ginseng) and Panax quinquefolium Linn.…”

Section: Discussionmentioning

confidence: 99%

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

This paper assessed the evidence of Panax notoginseng preparations in patients suffering from UAP using meta-analysis and systematic review methods. Methods were according to the Cochrane Handbook and analysed using Revman 5.3. A search of PubMed, Cochrane Library, Embase, MEDLINE, Chinese national knowledge infrastructure (CNKI), Vip information database, Wanfang data and Chinese Biomedical Literature Database (SinoMed) was conducted to identify randomized controlled trials (RCTs) of P. notoginseng preparations on UAP regardless of blinding, sex and language. The outcomes include all-cause mortality, cardiac mortality, cardiovascular events, UAP symptoms, improvement of electrocardiogram and adverse events. Eighteen RCTs including 1828 patients were identified. The level of reporting is generally poor. Among 18 studies, 16 studies were prescribed P. notoginseng injections, and two studies were oral P. notoginseng preparations. Reduction of cardiovascular events (RR:0.35;95% CI:0.13 to 0.94), alleviation of angina pectoris symptoms (RR:1.23;95% CI 1.18 to 1.29), improvement of ECG (RR:1.22;95% CI 1.15 to 1.28) and reduced frequency of angina pectoris (MD:-1.48; 95% CI -2.49 to -0.48) were observed. Cardiac mortality and duration of angina pectoris were not statistically significant. Panax notoginseng is beneficial to UAP patients; the results of these reviews may have important implications to clinical work. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

“…In addition, PNS was found to increase the expression of IkappaBalpha, whereas attenuating the expression of NF-kappaB/p65, suggesting that the possible mechanism responsible for the effect of PNS was associated with NF-kappaB signalling pathway, which was accompanied with inflammatory response. PNS inhibits zymosan A induced atherogenesis by suppressing phosphorylation of FAK on threonine 397, integrins expression, and NF-kappaB translocation in rats [58]. The similar trend of the inhibitory effects of PNS and its two major individual ingredients, ginsenoside Rg1 and ginsenoside Rb1, on the TNF-alpha-induced NF-kappaB activation was investigated in human coronary artery endothelial cells (HCAECs) [59].…”

Section: Cardiovascular Pharmacologymentioning

confidence: 99%

Protective Effects of Panax Notoginseng Saponins on Cardiovascular Diseases: A Comprehensive Overview of Experimental Studies

Yang

Xiong

Wang

et al. 2014

Evidence-Based Complementary and Alternative Medicine

125

View full text Add to dashboard Cite

Panax notoginseng saponins (PNS) are one of the most important compounds derived from roots of the herb Panax notoginseng which are traditionally used as a hemostatic medicine to control internal and external bleeding in China for thousands of years. To date, at least twenty saponins were identified and some of them including notoginsenoside R1, ginsenoside Rb1, and ginsenoside Rg1 were researched frequently in the area of cardiovascular protection. However, the protective effects of PNS on cardiovascular diseases based on experimental studies and its underlying mechanisms have not been reviewed systematically. This paper reviewed the pharmacology of PNS and its monomers Rb1, Rg1, and R1 in the treatment for cardiovascular diseases.

show abstract

Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-κB translocation

Cited by 49 publications

References 20 publications

Notoginsenoside R1 Protects HUVEC Against Oxidized Low Density Lipoprotein (Ox-LDL)-Induced Atherogenic Response via Down-Regulating miR-132

Notoginsenoside R1 Protects HUVEC Against Oxidized Low Density Lipoprotein (Ox-LDL)-Induced Atherogenic Response via Down-Regulating miR-132

Panax notoginsengPreparations for Unstable Angina Pectoris: A Systematic Review and Meta-Analysis

Protective Effects of Panax Notoginseng Saponins on Cardiovascular Diseases: A Comprehensive Overview of Experimental Studies

Contact Info

Product

Resources

About